Skip to main content
NCBI home page
ACS Central Science logoLink to ACS Central Science
. 2021 Dec 2;8(1):10–21. doi: 10.1021/acscentsci.1c00866

Fe-Curcumin Nanozyme-Mediated Reactive Oxygen Species Scavenging and Anti-Inflammation for Acute Lung Injury

Renyikun Yuan †,⊥, Yuqing Li §, Shan Han †, Xinxin Chen †, Jingqi Chen ‡, Jia He †, Hongwei Gao †,*, Yang Yang §,∥,*, Shilin Yang †, Yu Yang ‡,*
PMCID: PMC8796308  PMID: 35106369

Abstract

graphic file with name oc1c00866_0009.jpg

Pneumonia, such as acute lung injury (ALI), has been a type of lethal disease that is generally caused by uncontrolled inflammatory response and excessive generation of reactive oxygen species (ROS). Herein, we report Fe-curcumin-based nanoparticles (Fe-Cur NPs) with nanozyme functionalities in guiding the intracellular ROS scavenging and meanwhile exhibiting anti-inflammation efficacy for curing ALI. The nanoparticles are noncytotoxic when directing these biological activities. Mechanism studies for the anti-inflammation aspects of Fe-Cur NPs were systematically carried out, in which the infected cells and tissues were alleviated through downregulating levels of several important inflammatory cytokines (such as TNF-α, IL-1β, and IL-6), decreasing the intracellular Ca2+ release, inhibiting NLRP3 inflammasomes, and suppressing NF-κB signaling pathways. In addition, we performed both the intratracheal and intravenous injection of Fe-Cur NPs in mice experiencing ALI and, importantly, found that the accumulation of such nanozymes was enhanced in lung tissue (better than free curcumin drugs), demonstrating its promising therapeutic efficiency in two different administration methods. We showed that the inflammation reduction of Fe-Cur NPs was effective in animal experiments and that ROS scavenging was also effectively achieved in lung tissue. Finally, we revealed that Fe-Cur NPs can decrease the level of macrophage cells (CD11bloF4/80hi) and CD3+CD45+ T cells in mice, which could help suppress the inflammation cytokine storm caused by ALI. Overall, this work has developed the strategy of using Fe-Cur NPs as nanozymes to scavenge intracellular ROS and as an anti-inflammation nanodrugs to synergistically cure ALI, which may serve as a promising therapeutic agent in the clinical treatment of this deadly disease. Fe-Cur NP nanozymes were designed to attenuate ALI by clearing intracellular ROS and alleviating inflammation synergistically. Relevant cytokines, inflammasomes, and signaling pathways were studied.

Short abstract

Fe-Cur NP nanozymes were designed to attenuate ALI by clearing intracellular ROS and alleviating inflammation synergistically. Relevant cytokines, inflammasomes, and signaling pathways were studied.

1. Introduction

The COVID-19 pandemic has resulted in more than five million deaths worldwide so far, causing lung complications such as pneumonia and, in more severe cases, leading to acute respiratory distress syndrome or acute lung injury (ALI).1,2 Among them, ALI represents one of the most severe forms of the viral infection, bringing damage to alveolar epithelium and lung capillary endothelial cells, overwhelming pulmonary inflammation, and pulmonary edema as well as refractory hypoxemia, which may consequently develop into respiratory failure in critically ill patients.3−6 Pathogenesis studies reveal that the progression of ALI is directly related to the excessive generation of reactive oxygen species (ROS) causing oxidative injury in the inflamed lungs even throughout the entire body.4,7

Current therapies of ALI mainly rely on inhaling vasodilator gases like nitric oxide (NO) for increasing blood flow in ventilated areas (to relieve hypoxemia)8 or injecting pharmaceutical drugs including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitors and glucocorticoids to downregulate inflammatory cytokines.9,10 Nevertheless, they are limited by their inefficiency to fundamentally neutralize the overproduced ROS in inflamed lung areas, thus resulting in low objective response in treatment, poor prognosis, and high treatment cost.11,12 Therefore, developing a multifunctional nanomedicine with ROS scavenging ability and, at the same time, with anti-inflammation capacity would be a promising strategy to treat ALI.

Nanozymes are nanomaterial-based catalysts with enzyme mimicking properties. They are recognized as promising enzyme alternatives in biomedicine, mainly due to their high enzymatic activity, designability, physiological stability, and low production cost.13−16 Among the diversified nanozymes, Fe-based biocatalysts have attracted specific attention in diagnosis and disease treatment benefiting from their biosafety and efficiency in clearing intracellular ROS.17−19 In this work, we coordinated iron with an anti-inflammatory drug curcumin to prepare Fe-curcumin-based nanoparticles (Fe-Cur NPs) to achieve synergistic ROS scavenging and anti-inflammation for treating ALI for the first time. In particular, we systematically studied the mechanisms of our Fe-Cur NP treatment both in vitro and vivo. Results demonstrated that the secretion of several important inflammation cytokines like tumor necrosis factor-α (TNF-α) and interlukin-6 (IL-6) could be downregulated, inflammasomes such as a nucleotide-binding and oligomerization domain (NOD)-like receptor 3 (NLRP3) were suppressed, and ALI-related high intracellular Ca2+ levels were controlled. Further treating mice experiencing ALI, we found that the Fe-Cur NPs could be applied in two independent administration methods, through intratracheal injection (i.t.) or though intravenous injection (i.v.). The intracellular ROS scavenging as well as inflammation control were realized in vivo as well, and lung tissues were almost back to normal after such nanozyme treatment, demonstrating the effectiveness and promise of our Fe-Cur NPs for curing ALI and helping more COVID-19-infected patients to survive.

2. Results and Discussion

2.1. Preparation and Characterization of the Fe-Cur NPs

The Fe-Cur NPs were synthesized by adding curcumin to an FeCl3 and poly(vinylpyrrolidone) (PVP) mixture (dispersed in methanol) in a dropwise manner, in which the PVP was used to promote the formation of Fe-Cur NPs with better water dispersity (upper panel of Figure 1a). Upon reaction, the solution turned from yellow to deep-dark, indicating that the Fe3+ was coordinated with phenol groups of curcumin. The morphology and elemental mapping of Fe-Cur NPs were characterized by transmission electron microscope (TEM), showing the copresence of C, O, and Fe elements and their even distribution (Figure 1b, S1). X-ray diffraction (XRD) further indicated that the Fe-curcumin nanoconjugates were amorphous (Figure S2a). In addition, the particles also exhibited good stability within 1 week in water, phosphate buffered saline (PBS), and cell culture medium (Dulbecco’s modified eagle’s medium or DEME), with close hydrodynamic size at ∼12 nm (Figure 1c). The UV–vis adsorption wavelength of the particles was around 400 nm (Figures 1d and S3); and X-ray photoelectron spectroscopy (XPS) results demonstrated two strong binding energy peaks at 711 and 724 eV for Fe 2p3/2 and 2p1/2 respectively (Figure 1e),20 as well as the C-related bonds in curcumin (Figure 1f).21 All these data together confirmed that the Fe was associated with curcumin in our prepared nanoparticles.

Figure 1.

Figure 1

Open in a new tab

Synthesis and characterization of Fe-Cur NPs. (a) Schematic illustration of Fe-Cur NP synthesis and Fe-Cur NP based treatment for ALI in mice. (b) TEM mapping of Fe-Cur NPs, showing the main elements in nanoparticles. (c) Hydrodynamic sizes of Fe-Cur NPs in different solutions (determined by DLS). (inset) Dispersity and stability of NPs in water, PBS, and DMEM. (d) UV spectra of Fe-Cur NPs. (e and f) XPS spectra of Fe and C in Fe-Cur NPs, respectively.

2.2. ROS Scavenging Ability of Fe-Cur NPs in Vitro

During the progression of ALI and its related inflammatory disorders, ROS are generated to regulate inflammation; however, excessive ROS are harmful and can lead to severe lung tissue injury.9 Therefore, clearing excessive ROS is a strategy to attenuate ALI and the inflammation response in lungs. Since the Fe-based nanomaterials can be used as nanozymes for scavenging ROS,13 and polyphenols such as curcumin are recognized as natural antioxidants to reduce inflammation,22,23 we first studied the catalytic activities of our Fe-Cur NPs toward various substrates, ranging from 1-diphenyl-2-picrylhydrazyl (DPPH), 2,2′-azinobis(3-ethylbenzthiazoline-6-sulfonate) (ABTS) to Methylene Blue (MB). Notably, nearly 90% DPPH and ABTS were oxidized by adding 25 μg/mL Fe-Cur NPs, indicating their quite effective ROS scavenging ability (Figure 2a,b). To understand the catalytic mechanisms, we then reacted the nanomaterials with MB, which can digest •OH generated during Fenton reactions.24 As expected, more MB substrates were oxidized when gradually increasing the concentration of Fe-Cur NPs (Figure 2c), reaching a plateau of ∼80% (Figure S2b).

Figure 2.

Figure 2

Open in a new tab

ROS scavenging ability of Fe-Cur NPs in vitro. (a) DPPH radical scavenging and (b) ABTS radical scavenging ratio of the Fe-Cur NPs. (c) Concentration-dependent catalysis of NPs toward MB based on its UV–vis absorption. (d) ROS fluorescence intensity in J774A.1 cells, determined by flow cytometry. (e) Statistical results of d. (f) Cell viability of J774A.1 cells under H2O2 with/without Fe-Cur NPs. (g) ROS level in cells (ROS stained by DCFH2-DA and analyzed by fluorescence microscopy). (h) ROS level in J774A.1 cells under H2O2 with/without Fe-Cur NPs, detected by flow cytometry. (i) Statistical results of h. **P < 0.01 and ***P < 0.001.

To further investigate the ROS clearance in cells, we stimulated J774A.1 cells by lipopolysaccharide (LPS)/ATP to induce intracellular ROS,25,26 followed by Fe-Cur NPs treatment. The ROS level in cells was reflected by using a flow cytometry assay, in which cells with more ROS generation (screened by 2′-7′dichlorofluorescin diacetate, DCFH2-DA) would be more fluorescent. After LPS/ATP treatment, the cells emitted higher fluorescence (Figure 2d,e). Although the curcumin drug alone failed to scavenge the ROS yet even further provoked ROS enhancement, the Fe-Cur NPs were quite effective to help the J774A.1 cells get back to normal. Additionally, the ROS scavenging effect of the Fe-Cur NPs was further confirmed in H2O2-induced J774A.1 macrophage cells. As shown in Figure 2f, Fe-Cur NPs attenuated H2O2-induced cell death, in the presence of up to 80 μM H2O2. Similarly, staining the ROS by DCFH2-DA after H2O2 incubation, we also observed the significant ROS clearance ability of the Fe-Cur NPs according to the fluorescence microscopy and flow cytometry (Figures 2g–i). Collectively, these data indicated that Fe-Cur NPs have strong ROS scavenging ability in vitro.

2.3. Fe-Cur NPs Exhibited an Anti-Inflammation Effect in LPS-Stimulated Macrophage Cells

Since the biosafety of the nanozymes is critical for developing them to cure ALI, we next studied the cytotoxicity of the Fe-Cur NPs by 4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and, then, investigated relevant protein expressions by Western blotting assay and immunofluorescence methods (Figure 3a). As shown in Figure 3b, although the LPS/ATP stimulation deteriorated cell viability, after treating the weak cells by 0.1 μg/mL Fe-Cur NPs, the cell health was almost recovered, demonstrating the nontoxic nature of the Fe-Cur NPs.

Figure 3.

Figure 3

Open in a new tab

Anti-inflammatory effects of Fe-Cur NPs on LPS/ATP-induced J774A.1 cells. (a) Schematic illustration of the experiment carried out here. (b) Cell viability of J774A.1 cells determined by MTT assays. (c and d) TNF-α and IL-6 levels were detected by ELISA. (e) Indicated protein expression detected by Western blotting assay. (f) IL-1β levels detected by ELISA kits. (g) Plasmids of OFPSpark-NEK7 and EGFP-NLRP3 activation determined by immunofluorescence. (h) Cleaved-caspase-1 activation determined by immunofluorescence. (i) Indicated protein expression detected by Western blotting assay. ##P < 0.01, ###P < 0.001 vs control group; *P < 0.05, **P < 0.01, and ***P < 0.001 vs LPS/ATP alone group.

The levels of several inflammatory cytokines involved in ALI progression, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), are next determined due to their positive correlation with the disease development.27−29 As indicated by Figure 3c,d, the LPS/ATP-stimulation increased TNF-α and IL-6 levels in J774A.1 cells, while Fe-Cur NP treatment effectively decreased their expression, being close to the TNF-α and IL-6 expression amount in cells without LPS/ATP incubation. Importantly, the curcumin drug itself was also useful in downregulating the related cytokines, yet it was not as good as the Fe-Cur NPs, indicating the possible synergistic effect of the conjugates in scavenging ROS and suppressing cytokines for relieving inflammation.

Moreover, in the deterioration of ALI, inflammasomes especially the nucleotide-binding and oligomerization domain (NOD) like receptor 3 (NLRP3) type are also involved in cytoplasm responding to pathogens infections.30−32 Therefore, we next checked the NLRP3 inflammasome and its related cell components to better understand the anti-inflammatory mechanisms of the Fe-Cur NPs. First, after LPS/ATP stimulation, the NLRP3 inflammasome and the expression of cleaved caspase-1 as well as mature IL-1β were all overexpressed, leading to neutrophil recruitment (Figure 3e,f). At the same time, an important component of NLRP3, called NIMA-related kinase 7 (NEK7),33,34 was stimulated; another important cell signaling pathway in inflammation known as the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) was activated (Figure 3g).35,36 Then, by having the Fe-Cur NPs or curcumin drug, these cell elements were all mediated back to normal, verifying the efficacy of this nanozyme in anti-inflammation.

To visualize the anti-inflammatory process in living cells, we also carried out immunofluorescence assays, by using NEK7 or NLRP3 plasmid transfected J774A.1 cells. The immunofluorescence results confirmed that the Fe-Cur NPs were useful to decrease the fluorescence intensity in the cytoplasm (Figure 3h,i). Together, these data demonstrated the ability of Fe-Cur NPs in eliminating inflammation, mainly through inhibiting the secretion of TNF-α and IL-6 and the suppression of NLRP3 inflammasome and NF-κB pathway.

2.4. Fe-Cur NPs Downregulated Intracellular Ca2+ Levels

Calcium ions (Ca2+) have a critical regulatory role in inflammatory response, and studies have shown that elevated intracellular Ca2+ concentrations could trigger mitochondrial destabilization, therefore leading to the production of ROS and activating the NLRP3 inflammasome to accelerate the inflammation.37−39 Based on these findings, we are interested in whether the Fe-Cur NPs can also mediate abnormal Ca2+ levels for ALI. To this end, the same treatment was carried out on J774A.1 cells by LPS/ATP, and a Ca2+-related essential lipid phosphatidylinositol biphosphate (PIP2) was studied (Figure 4a). The PIP2 pathway on the membrane can control the Ca2+ release out of the endoplasmic reticulum.40,41 As indicated by flow cytometry assays (Figure 4b,c), the level of Ca2+ significantly increased in LPS/ATP treatment cells, while Fe-Cur NPs suppressed the Ca2+ release, indicating their activity in downregulating the intracellular Ca2+ concentration. We further examined the level of calcium by using EGFP-Ca2+ plasmid transfected J774A.1 cells, and immunofluorescence showed a consistent trend (Figure 4d).

Figure 4.

Figure 4

Open in a new tab

Fe-Cur NPs downregulated the intracellular Ca2+ level. (a) Schematic illustration of the experiment carried out here. (b) Fluorescence intensity of Ca2+ assessed by flow cytometry. (c) Relative intensity of b. (d) Plasmid of EGFP-Ca2+ fluorescence determined by immunofluorescence. (e) Expression of PIP2, PLCγ2, DAG Lipaseα, and IP3 Receptor1 detected by Western blotting assay. ###P < 0.001 vs control group; *P < 0.05, **P < 0.01, and ***P < 0.001 vs LPS/ATP alone group.

Next, the expression of calcium-related proteins was also determined by Western blotting. The results displayed that LPS/ATP upregulated the protein expression involved in the PIP2 pathways (such as the PIP2, and its hydrolyzed product diacylglycerol (DAG) and inositol triphosphate (IP3)42), but the Fe-Cur NPs or curcumin drug can again decrease those protein levels (Figure 4e). Therefore, the effectiveness of the Fe-Cur NPs in alleviating inflammation was also confirmed by studying the Ca2+-related cell components, which was very consistent with our aforementioned results.

2.5. Delivering Fe-Cur NPs for Curing Mice Experiencing ALI

Since ALI can be a deadly disease that deteriorates or even deprives lung function, and the excessive ROS level along with various inflammatory responses during its progression offer us an opportunity to restore cell health, scavenging ROS together with reducing inflammation could be a potential therapy for ALI.9,43,44 After demonstrating its effectiveness in vitro, we then wanted to investigate in vivo performance in two independent administration methods, through intratracheal injection (i.t.) or intravenous injection (i.v.). We first studied the biodistribution of Fe-Cur NPs in different tissues of mice, by using these two different injection methods (Figure 5a). The biodistributions of Fe-Cur NPs were detected by UPLC-MS/MS.45,46 In intratracheal injection, interestingly, the inhaled Fe-Cur NPs and curcumin drug were notably accumulated more in the lungs than in the other organs, and the nanoparticles were even more effective than the free drug molecule (Figure 5b), mainly due to the better penetrating ability of Fe-Cur NPs (Figure S4). Then, for the traditional intravenous injection, compared with free curcumin drug, Fe-Cur NPs also showed enhanced accumulation in the lung, consistent with the results of i.t. injection (Figure 5c). Probably due to prolonged blood circulation and the enhanced permeability and retention (EPR) effect, the nanomedicine selectively accumulated to the inflammatory site.47

Figure 5.

Figure 5

Open in a new tab

Fe-Cur NP treatment for mice experiencing ALI. (a) Experiment schedule of ALI mice study. (b) Distribution rate of Fe-Cur NPs and curcumin in heart, liver, spleen, lung, and kidney at 4 h, through intratracheal injection (i.t.). (c) Distribution rate of Fe-Cur NPs and curcumin in heart, liver, spleen, lung, and kidney at 4 h, through intravenous injection (i.v.). (d) H&E staining of the lung tissues in i.t. and i.v. treated groups, respectively (H&E, original magnification, 200×). DEX (5 mg/kg, i.p.) was used as a positive control. (e) Blood concentration versus time profiles for Fe-Cur NPs following tail vein injection to rats. (f) Mouse lungs were weighed and used to calculate lung index. Data are means ± SEM (n = 3–5). *P < 0.05, **P < 0.01, and ***P < 0.001 vs LPS alone group.

Encouraged by these results, we further evaluated the therapeutic effect of Fe-Cur NPs after i.t. and i.v. administration respectively using LPS/ATP-induced ALI in mice as a model. After sacrificing the mice, their lung tissues were collected. First, hematoxylin and eosin (H&E) staining experiments were carried out to show that the LPS/ATP-induced ALI mice were indeed exhibited destructed alveoli structures, interstitial exudation of alveoli, and infiltration of inflammatory cells (Figure 5d). Based on that, free curcumin drug showed moderately relieved lesions in lung tissues, while Fe-Cur NPs exhibited obviously higher therapeutic efficiency in ALI mice, in which the alveoli structures in lung tissues were largely recovered. This result is also consistent with the positive control group treated by dexamethasone (DEX) (Figure 5d). Then the blood circulation half-life of Fe-Cur NPs after i.v. injection was evaluated, and he result showed that the fast half-life is 0.03260 h and the slow half-life is 13.44 h (Figure 5e). Furthermore, the lung index increased in LPS-induced ALI mice, Fe-Cur NPs have a better effect on decreasing the lung index compared to administration of free curcumin drug (Figure 5f).

To demonstrate the lung function of mice experiencing ALI after Fe-Cur NP treatment, the resistance of lung (RL), resistance of expiration (Re), and respiratory lung compliance (Cdyn) levels in mice were then detected using an AniRes2005 lung function test system. Results showed that the Fe-Cur NPs could obviously reverse the lung function index, while curcumin alone had little effect on lung function (Figures 6a–c). Considering that the Fe-Cur NPs have a ROS scavenging effect in vitro and that the production of ROS contributes to lung injury,48 we also studied the effect of Fe-Cur NPs on scavenging ROS in vivo, by using a ROS kit and immunofluorescence of lung tissues. As vividly shown in Figure 6g (fluorescence intensities were quantified in Figure 6d), the Fe-Cur NPs demonstrated significant ROS scavenging ability both after i.t. and i.v. administration, and they were more effective than free curcumin drugs. In addition, the level of malondialdehyde49 and myeloperoxidase,12 which are important to defend the neutralization of ROS production, increased significantly in ALI mice; however, Fe-Cur NP treatment decreased their levels, validating the ability of such nanozymes in removing ROS in mice bodies (Figure 6e,f).

Figure 6.

Figure 6

Open in a new tab

Fe-Cur NP treatment for the mice experiencing ALI. (a) Resistance of lung (RL), (b) resistance of expiration (Re), and (c) respiratory lung compliance (Cdyn) levels were detected using an AniRes2005 lung function test system. (d–f) Lung tissue of mice was collected to determine the level of ROS, MDA, and MPO with an ELISA kit. (g) Fluorescence images of ROS stained lung slices. ###P < 0.001 vs control group; *P < 0.05, **P < 0.01, and ***P < 0.001 vs LPS/ATP alone group.

Furthermore, we also determined whether the lung inflammatory cytokine storm could be attenuated by Fe-Cur NPs in ALI mice. The levels of TNF-α, IL-1β, and IL-6 expressions in lung tissues were determined by ELISA kit, and we found that the Fe-Cur NPs both decreased their levels in lung tissues after i.t. and i.v. administration, and this was also as effective as the model drug DEX (Figures 7a–c). The Fe-Cur NPs were effective in decreasing TNF-α, IL-1β, and IL-6 levels in serum and bronchoalveolar lavage fluid (BALF) after i.t. and i.v. administration (Figures S5a–f). Taken together, it is worth knowing that the downregulating inflammatory factors of Fe-Cur NPs are better than that of the curcumin drug in vivo (both in i.t. and in i.v.). Since the infiltration of immune cells facilitates the inflammation cytokine storm in pneumonia mainly through affecting the macrophages and T cells in the lung,50 we detected the macrophage cells (CD11bloF4/80hi) in the lungs of ALI mice. The macrophage cells were activated and shift to M1 phenotype, while Fe-Cur NPs decreased the level of CD11bloF4/80hi cells compared with mice treated with Cur both after i.t. and i.v. administration (Figure 7d,e). We further detected the CD3+CD45+ T cells, which was significantly lower in Fe-Cur NPs treated mice than in those treated with Cur after i.v. administration (Figure 7f,g). Finally, the potential in vivo toxicity of Fe-Cur NPs was evaluated. The blood routine data for Fe-Cur NPs treated mice were all found to be normal (Figures 8a–i). And as observed in H&E staining imaging, the Fe-Cur NPs have almost no toxicity on the heart, liver, spleen, lung, and kidney (Figure 8j). These results together demonstrated that the Fe-Cur NPs are effective and safe in treating the ALI.

Figure 7.

Figure 7

Open in a new tab

Fe-Cur NP treatment for the mice experiencing ALI. (a–c) Lung tissue of mice was collected to determine the inflammatory cytokines TNF-α, IL-1β, and IL-6 with an ELISA kit. (d) Representative plots of CD11bloF4/80hi cells as a percentage of the total CD45+ cell population (e) and corresponding quantification results in all cells (d) after various treatments. (f) Representative plots of CD3+ in CD45+ cells after various treatments. (g) Statistical significance of f. ###P < 0.001 vs control group; *P < 0.05, **P < 0.01, and ***P < 0.001 vs LPS/ATP alone group.

Figure 8.

Figure 8

Open in a new tab

Toxicity of Fe-Cur NPs in vivo. (a–i) Blood panel data of normal mice (blank) and mice post Fe-Cur NP injection at different time points (1, 14, and 30 days). (j) H&E staining of heart, liver, spleen, lung, kidney after Fe-Cur NP treatment at different time points (1, 14, and 30 days).

3. Conclusion

In summary, we have developed a nanozyme Fe-Cur NPs, for the first time, to clear intracellular ROS and synergistically alleviate inflammation during the progression of ALI. To better understand the nanozyme-based disease treatment, we systematically studied important inflammatory cytokines (such as TNF-α and IL-6), NLRP3 inflammasome, intracellular Ca2+-related signaling pathways, and infiltration of immune cells. The Fe-Cur NPs both showed in vitro and in vivo that the ROS production and inflammation mediators could be effectively suppressed. The Ca2+ level indicating inflammation was also downregulated after treatment. Interestingly, we found that both the intratracheal and intravenous injection of Fe-Cur NPs in mice experiencing ALI were effective, therefore providing two independent treatment strategies in relieving this deadly disease. This work may also help to decrease the number of deaths during the COVID-19 pandemic.

Acknowledgments

This work was supported by National Program on Key Basic Research Project (2020YFA0211100), National Natural Science Foundation of China (51922077, 51872205, 22107065), the Foundation of National Facility for Translational Medicine (Shanghai) (TMSK-2020-012), Young talents program, Shanghai Municipal Commission of Heath and Family Planning Foundation (2017YQ050), the Guangxi Science and Technology Base and Talent Special Project (2018AD19034, China), the project of Guangxi overseas “100 persons’ plan” high-level expert, the Innovation Project of Guangxi Graduate Education (YCSW2019176, China), and Qihuang High-level Talent Team Cultivation Project of Guangxi University of Chinese Medicine (2021002).

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acscentsci.1c00866.

  • Materials and methods and additional figures (PDF)

Author Contributions

# R.Y., Y.L., and S.H. contributed equally to this work.

The authors declare no competing financial interest.

Supplementary Material

oc1c00866_si_001.pdf (537.5KB, pdf)

References

  1. Gallelli L.; Zhang L.; Wang T.; Fu F. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. J. Clin. Pharmacol. 2020, 60 (7), 815. 10.1002/jcph.1644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Mitchell W. B. Thromboinflammation in COVID-19 acute lung injury. Paediatric Respiratory Reviews 2020, 35, 20. 10.1016/j.prrv.2020.06.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Matthay M. A.; Robriquet L.; Fang X. Alveolar epithelium: role in lung fluid balance and acute lung injury. Proc. Am. Thorac. Soc. 2005, 2 (3), 206. 10.1513/pats.200501-009AC. [DOI] [PubMed] [Google Scholar]
  4. Chow C.-W.; Herrera Abreu M. T.; Suzuki T.; Downey G. P. Oxidative stress and acute lung injury. Am. J. Respir. Cell Mol. Biol. 2003, 29 (4), 427. 10.1165/rcmb.F278. [DOI] [PubMed] [Google Scholar]
  5. Li L.; Huang Q.; Wang D. C.; Ingbar D. H.; Wang X. Acute lung injury in patients with COVID-19 infection. Clinical and Translational Medicine 2020, 10 (1), 20. 10.1002/ctm2.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gallelli L.; Zhang L.; Wang T.; Fu F. Severe acute lung injury related to COVID-19 infection: A review and the possible role for escin. J. Clin. Pharmacol. 2020, 60 (7), 815. 10.1002/jcph.1644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lei J.; Wei Y.; Song P.; Li Y.; Zhang T.; Feng Q.; Xu G. Cordycepin inhibits LPS-induced acute lung injury by inhibiting inflammation and oxidative stress. Eur. J. Pharmacol. 2018, 818, 110. 10.1016/j.ejphar.2017.10.029. [DOI] [PubMed] [Google Scholar]
  8. Taylor R. W.; Zimmerman J. L.; Dellinger R. P.; Straube R. C.; Criner G. J.; Davis K. Jr; Kelly K. M.; Smith T. C.; Small R. J.; Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. Jama 2004, 291 (13), 1603. 10.1001/jama.291.13.1603. [DOI] [PubMed] [Google Scholar]
  9. Kellner M.; Noonepalle S.; Lu Q.; Srivastava A.; Zemskov E.; Black S. M.; Wang Y.-X. ROS Signaling in the Pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). Pulmonary Vasculature Redox Signaling in Health and Disease. Adv. Exp. Med. Biol. 2017, 967, 1. 10.1007/978-3-319-63245-2_8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Tu G.-w.; Shi Y.; Zheng Y.-j.; Ju M.-j.; He H.-y.; Ma G.-g.; Hao G.-w.; Luo Z. Glucocorticoid attenuates acute lung injury through induction of type 2 macrophage. J. Transl. Med. 2017, 15 (1), 1. 10.1186/s12967-017-1284-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kellner M.; Noonepalle S.; Lu Q.; Srivastava A.; Zemskov E.; Black S. M. ROS Signaling in the Pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). Adv. Exp. Med. Biol. 2017, 967, 105. 10.1007/978-3-319-63245-2_8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nieman G. F.; Gatto L. A.; Andrews P.; Satalin J.; Camporota L.; Daxon B.; Blair S. J.; Al-khalisy H.; Madden M.; Kollisch-Singule M.; et al. Prevention and treatment of acute lung injury with time-controlled adaptive ventilation: physiologically informed modification of airway pressure release ventilation. Ann. Intensive Care 2020, 10 (1), 3. 10.1186/s13613-019-0619-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wang H.; Wan K.; Shi X. Recent advances in nanozyme research. Adv. Mater. 2019, 31 (45), 1805368. 10.1002/adma.201805368. [DOI] [PubMed] [Google Scholar]
  14. Jiang D.; Ni D.; Rosenkrans Z. T.; Huang P.; Yan X.; Cai W. Nanozyme: new horizons for responsive biomedical applications. Chem. Soc. Rev. 2019, 48 (14), 3683. 10.1039/C8CS00718G. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wang Q.; Wei H.; Zhang Z.; Wang E.; Dong S. Nanozyme: An emerging alternative to natural enzyme for biosensing and immunoassay. TrAC, Trends Anal. Chem. 2018, 105, 218. 10.1016/j.trac.2018.05.012. [DOI] [Google Scholar]
  16. Li Y.; Liu J. Nanozyme’s catching up: activity, specificity, reaction conditions and reaction types. Mater. Horiz. 2021, 8 (2), 336. 10.1039/D0MH01393E. [DOI] [PubMed] [Google Scholar]
  17. Gao L.; Fan K.; Yan X. Iron oxide nanozyme: A multifunctional enzyme mimetics for biomedical application. Nanozymology 2020, 105. 10.1007/978-981-15-1490-6_5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kong F.; Bai H.; Ma M.; Wang C.; Xu H.; Gu N.; Zhang Y. Fe3O4@ Pt nanozymes combining with CXCR4 antagonists to synergistically treat acute myeloid leukemia. Nano Today 2021, 37, 101106. 10.1016/j.nantod.2021.101106. [DOI] [Google Scholar]
  19. Xu Y.; Xue J.; Zhou Q.; Zheng Y.; Chen X.; Liu S.; Shen Y.; Zhang Y. The Fe-N-C Nanozyme with Both Accelerated and Inhibited Biocatalytic Activities Capable of Accessing Drug–Drug Interactions. Angew. Chem. 2020, 132 (34), 14606. 10.1002/ange.202003949. [DOI] [PubMed] [Google Scholar]
  20. Zhang R.; Cheng L.; Dong Z.; Hou L.; Zhang S.; Meng Z.; Betzer O.; Wang Y.; Popovtzer R.; Liu Z. Ultra-small natural product based coordination polymer nanodots for acute kidney injury relief. Mater. Horiz. 2021, 8 (4), 1314. 10.1039/D0MH00193G. [DOI] [PubMed] [Google Scholar]
  21. Singh A. K.; Yadav S.; Sharma K.; Firdaus Z.; Aditi P.; Neogi K.; Bansal M.; Gupta M. K.; Shanker A.; Singh R. K.; Prakash P. Quantum curcumin mediated inhibition of gingipains and mixed-biofilm of Porphyromonas gingivalis causing chronic periodontitis. RSC Adv. 2018, 8 (70), 40426. 10.1039/C8RA08435A. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Eybl V.; Kotyzova D.; Koutensky J. Comparative study of natural antioxidants–curcumin, resveratrol and melatonin–in cadmium-induced oxidative damage in mice. Toxicology 2006, 225 (2–3), 150. 10.1016/j.tox.2006.05.011. [DOI] [PubMed] [Google Scholar]
  23. Jovanovic S. V.; Boone C. W.; Steenken S.; Trinoga M.; Kaskey R. B. How curcumin works preferentially with water soluble antioxidants. J. Am. Chem. Soc. 2001, 123 (13), 3064. 10.1021/ja003823x. [DOI] [PubMed] [Google Scholar]
  24. Liu C.; Yang B.; Chen J.; Jia F.; Song S. Synergetic degradation of Methylene Blue through photocatalysis and Fenton reaction on two-dimensional molybdenite-Fe. J. Environ. Sci. 2022, 111, 11. 10.1016/j.jes.2021.03.001. [DOI] [PubMed] [Google Scholar]
  25. Shen R.; Yin P.; Yao H.; Chen L.; Chang X.; Li H.; Hou X. Punicalin Ameliorates Cell Pyroptosis Induced by LPS/ATP Through Suppression of ROS/NLRP3 Pathway. J. Inflammation Res. 2021, 14, 711. 10.2147/JIR.S299163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Liao P.-C.; Chao L. K.; Chou J.-C.; Dong W.-C.; Lin C.-N.; Lin C.-Y.; Chen A.; Ka S.-M.; Ho C.-L.; Hua K.-F. Lipopolysaccharide/adenosine triphosphate-mediated signal transduction in the regulation of NLRP3 protein expression and caspase-1-mediated interleukin-1β secretion. Inflammation Res. 2013, 62 (1), 89. 10.1007/s00011-012-0555-2. [DOI] [PubMed] [Google Scholar]
  27. Wang X.; Yan J.; Xu X.; Duan C.; Xie Z.; Su Z.; Ma H.; Ma H.; Wei X.; Du X. Puerarin prevents LPS-induced acute lung injury via inhibiting inflammatory response. Microb. Pathog. 2018, 118, 170. 10.1016/j.micpath.2018.03.033. [DOI] [PubMed] [Google Scholar]
  28. Samanta J.; Singh S.; Arora S.; Muktesh G.; Aggarwal A.; Dhaka N.; Kant Sinha S.; Gupta V.; Sharma V.; Kochhar R. Cytokine profile in prediction of acute lung injury in patients with acute pancreatitis. Pancreatology 2018, 18 (8), 878. 10.1016/j.pan.2018.10.006. [DOI] [PubMed] [Google Scholar]
  29. Lin S.; Wu H.; Wang C.; Xiao Z.; Xu F. Regulatory T Cells and Acute Lung Injury: Cytokines, Uncontrolled Inflammation, and Therapeutic Implications. Front. Immunol. 2018, 10.3389/fimmu.2018.01545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Grailer J. J.; Canning B. A.; Kalbitz M.; Haggadone M. D.; Dhond R. M.; Andjelkovic A. V.; Zetoune F. S.; Ward P. A. Critical role for the NLRP3 inflammasome during acute lung injury. J. Immunol. 2014, 192 (12), 5974. 10.4049/jimmunol.1400368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Zhang Y.; Li X.; Grailer J. J.; Wang N.; Wang M.; Yao J.; Zhong R.; Gao G. F.; Ward P. A.; Tan D.-X.; Li X. Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J. Pineal Res. 2016, 60 (4), 405. 10.1111/jpi.12322. [DOI] [PubMed] [Google Scholar]
  32. Long Y.; Liu X.; Tan X.-z.; Jiang C.-x.; Chen S.-w.; Liang G.-n.; He X.-m.; Wu J.; Chen T.; Xu Y. ROS-induced NLRP3 inflammasome priming and activation mediate PCB 118- induced pyroptosis in endothelial cells. Ecotoxicol. Environ. Saf. 2020, 189, 109937. 10.1016/j.ecoenv.2019.109937. [DOI] [PubMed] [Google Scholar]
  33. He Y.; Zeng M. Y.; Yang D.; Motro B.; Núñez G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 2016, 530 (7590), 354. 10.1038/nature16959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Chen Y.; Meng J.; Bi F.; Li H.; Chang C.; Ji C.; Liu W. NEK7 Regulates NLRP3 Inflammasome Activation and Neuroinflammation Post-traumatic Brain Injury. Front. Mol. Neurosci. 2019, 10.3389/fnmol.2019.00202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Liu Z.; Wang X.; Wang Y.; Zhao M. NLRP3 inflammasome activation regulated by NF-κB and DAPK contributed to paraquat-induced acute kidney injury. Immunol. Res. 2017, 65 (3), 687. 10.1007/s12026-017-8901-7. [DOI] [PubMed] [Google Scholar]
  36. Gross C. M.; Kellner M.; Wang T.; Lu Q.; Sun X.; Zemskov E. A.; Noonepalle S.; Kangath A.; Kumar S.; Gonzalez-Garay M.; et al. LPS-induced Acute Lung Injury Involves NF-κB-mediated Downregulation of SOX18. Am. J. Respir. Cell Mol. Biol. 2018, 58 (5), 614. 10.1165/rcmb.2016-0390OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Murakami T.; Ockinger J.; Yu J.; Byles V.; McColl A.; Hofer A. M.; Horng T. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (28), 11282. 10.1073/pnas.1117765109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Horng T. Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome. Trends Immunol. 2014, 35 (6), 253. 10.1016/j.it.2014.02.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Di A.; Mehta D.; Malik A. B. ROS-activated calcium signaling mechanisms regulating endothelial barrier function. Cell Calcium 2016, 60 (3), 163. 10.1016/j.ceca.2016.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Suh B.-C.; Kim D.-I.; Falkenburger B. H.; Hille B. Membrane-localized β-subunits alter the PIP2 regulation of high-voltage activated Ca2+ channels. Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (8), 3161. 10.1073/pnas.1121434109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Wong R.; Hadjiyanni I.; Wei H. C.; Polevoy G.; McBride R.; Sem K. P.; Brill J. A. PIP2 hydrolysis and calcium release are required for cytokinesis in Drosophila spermatocytes. Curr. Biol. 2005, 15 (15), 1401. 10.1016/j.cub.2005.06.060. [DOI] [PubMed] [Google Scholar]
  42. Falkenburger B. H.; Dickson E. J.; Hille B. Quantitative properties and receptor reserve of the DAG and PKC branch of G(q)-coupled receptor signaling. J. Gen. Physiol. 2013, 141 (5), 537. 10.1085/jgp.201210887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Li P. C.; Wang B. R.; Li C. C.; Lu X.; Qian W. S.; Li Y. J.; Jin F. G.; Mu D. G. Seawater inhalation induces acute lung injury via ROS generation and the endoplasmic reticulum stress pathway. Int. J. Mol. Med. 2018, 41 (5), 2505. 10.3892/ijmm.2018.3486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Forrester S. J.; Kikuchi D. S.; Hernandes M. S.; Xu Q.; Griendling K. K. Reactive Oxygen Species in Metabolic and Inflammatory Signaling. Circ. Res. 2018, 122 (6), 877. 10.1161/CIRCRESAHA.117.311401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Xu Y.; Bao S.; Tian W.; Wen C.; Hu L.; Lin C. Tissue distribution model and pharmacokinetics of nuciferine based on UPLC-MS/MS and BP-ANN. Int. J. Clin Exp Med. 2015, 8 (10), 17612. [PMC free article] [PubMed] [Google Scholar]; PMID 26770351; PMCID PMC4694251.
  46. Ye W.; Lin C.; Lin G.; Chen R.; Sun W.; Wang S.; Wang X.; Zhou Y. Tissue Distribution of Engeletin in Mice by UPLC-MS/MS. Curr. Pharm. Anal. 2019, 15 (6), 604. 10.2174/1573412914666180501114659. [DOI] [Google Scholar]
  47. Liu Y.; Sun D.; Fan Q.; Ma Q.; Dong Z.; Tao W.; Tao H.; Liu Z.; Wang C. The enhanced permeability and retention effect based nanomedicine at the site of injury. Nano Res. 2020, 13 (2), 564. 10.1007/s12274-020-2655-6. [DOI] [Google Scholar]
  48. Kellner M.; Noonepalle S.; Lu Q.; Srivastava A.; Zemskov E.; Black S. M. ROS Signaling in the Pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). Adv. Exp. Med. Biol. 2017, 967, 105. 10.1007/978-3-319-63245-2_8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Shamdani S.; Uzan G.; Naserian S. TNFα-TNFR2 signaling pathway in control of the neural stem/progenitor cell immunosuppressive effect: Different experimental approaches to assess this hypothetical mechanism behind their immunological function. Stem Cell Res. Ther. 2020, 11 (1), 307. 10.1186/s13287-020-01816-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Ma Q.; Fan Q.; Xu J.; Bai J.; Han X.; Dong Z.; Zhou X.; Liu Z.; Gu Z.; Wang C. Calming Cytokine Storm in Pneumonia by Targeted Delivery of TPCA-1 Using Platelet-Derived Extracellular Vesicles. Matter 2020, 3 (1), 287. 10.1016/j.matt.2020.05.017. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

oc1c00866_si_001.pdf (537.5KB, pdf)

Articles from ACS Central Science are provided here courtesy of American Chemical Society

RESOURCES